ReviR Therapeutics partners with Asieris to develop new oncology therapies
09 Feb 2023
License out/in
Preview
Source: Pharmaceutical Technology
ReviR and Asieris partner to discover and develop new treatments for genitourinary tumours and other related serious diseases. Credit: Herney Gómez / Pixabay.
Preview
Source: Pharmaceutical Technology
Revir Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics.
The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies.
Under the agreement, Asieris will use the advanced RNA modulation technologies, Binder and SpliceR, of ReviR for identifying and developing new therapies that target RNA for cancer treatment.
ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.
The company’s VoyageR AI platform integrates computational methods to drug traditionally undruggable RNA targets.
Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.
Asieris Pharmaceuticals discovers, develops, and markets advanced therapeutics to treat GU tumours and other related diseases.
ReviR Therapeutics chief scientific officer Paul August said: “Asieris is a global biopharma company specialised in the development of GU oncology therapies, and we are excited to be working with them to discover new treatments for indications of interests.
“Our BindeR and SpliceR platform technologies have the potential to advance therapeutics for undruggable cancer targets, and we believe this collaboration will accelerate the discovery of new treatments for patients.”
The company is focused on developing RNA-targeting small molecule therapies to treat cancer and other serious genetically defined diseases.
It uses technologies to develop therapeutics that modulate the target RNA, to develop disease-modifying treatments.
Asieris Translational Research head and Discovery Biology vice president Alice Chen said: “We are pleased to be collaborating with ReviR, an innovative biopharmaceutical company focused on the development of RNA-targeting small molecule therapies.
“We believe that our in-house R&D expertise on small molecule oncology drug discovery, combined with ReviR’s proprietary RNA-targeted technologies, will speed the benefit to patients.
“We will continue to adhere to our differentiated R&D strategy, focus on genitourinary tumours and related diseases, and expand the global reach of our innovation to deliver novel drug products for patients in China and globally.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
Preview
Source: Pharmaceutical Technology
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.